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Abstract
The link between estrogen and the development and proliferation
of breast cancer is well documented. Estrogen stimulates growth
and inhibits apoptosis through estrogen receptor-mediated
mechanisms in many cell types. Interestingly, there is strong
evidence that estrogen induces apoptosis in breast cancer and
other cell types. Forty years ago, before the development of
tamoxifen, high-dose estrogen was used to induce tumor
regression of hormone-dependent breast cancer in post-meno-
pausal women. While the mechanisms by which estrogen induces
apoptosis were not completely known, recent evidence from our
laboratory and others demonstrates the involvement of the extrinsic
(Fas/FasL) and the intrinsic (mitochondria) pathways in this
process. We discuss the different apoptotic signaling pathways
involved in E2 (17β-estradiol)-induced apoptosis, including the
intrinsic and extrinsic apoptosis pathways, the NF-κB (nuclear
factor-kappa-B)-mediated survival pathway as well as the PI3K
(phosphoinositide 3-kinase)/Akt signaling pathway. Breast cancer
cells can also be sensitized to estrogen-induced apoptosis through
suppression of glutathione by BSO (L-buthionine sulfoximine). This
finding has implications for the control of breast cancer with low-
dose estrogen and other targeted therapeutic drugs.
Introduction
Breast cancer is one of the most frequently diagnosed
cancers among women, with an estimated 184,450 new
cases of invasive disease and 40,930 deaths in 2008. There
is strong evidence that estrogen plays a role in its
development and progression [1]. Breast cancer was first
recognized to be estrogen-dependent when the British
surgeon George Beatson [2] published his findings of the
beneficial effects of oophorectomy in a pre-menopausal
patient with advanced breast cancer. Beatson had based his
approach on the role of the ovaries in mammalian lactation
and presumed that there would be a similar mechanism for
breast cancer growth. Since that time, there has been an
expanding clinical database that implicates estrogen in the
development and progression of breast cancer. Evidence to
support this conclusion comes from clinical studies of
hormone replacement therapy, which were initially designed
to determine the benefits of replacement approaches on
post-menopausal women’s health [3,4], and the successful
clinical strategy of treating breast cancer by blocking
estrogen action using the anti-estrogen tamoxifen [5] or
preventing estrogen synthesis using aromatase inhibitors
(AIs) [6].
Estrogens are a class of sex steroid hormones that are
synthesized from cholesterol and are secreted primarily by
the ovaries, with secondary contributions from placenta,
adipose tissue, testes, and adrenal glands. After menopause,
ovarian estrogen biosynthesis is minimal, with circulating
estrogens being derived principally from peripheral aromatiza-
tion of adrenal androgens. Estrogens are essential to the
function of the female reproductive system and are required
for the proliferation and differentiation of healthy breast
epithelium. Estrogens occur naturally in several structurally
related forms; however, the predominant intracellular estro-
gen is 17β-estradiol (E2). In mammary glands, E2 promotes
cell proliferation in both normal and transformed epithelial
cells by modifying the expression of hormone-responsive
genes involved in the cell cycle and/or programmed cell
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death. In estrogen receptor (ER)-positive MCF-7 human
breast cancer cells, one of the principal mechanism by which
E2 stimulates growth is through the induction of G1- to
S-phase transition. This induction is associated with the rapid
and direct upregulation of c-myc, which controls cyclin D1
expression along with activation of cyclin-dependent kinase
(CDK) and phosphorylation of retinoblastoma protein [7]. E2
also rapidly activates cyclin E-CDK2 complexes, accelerating
the G1-to-S transition [8]. Additionally, E2 has ‘non-genomic
or membrane-initiated’ effects (that is, independent of
ER-mediated transcription) that occur within minutes after E2
administration [9-11]. Specifically, ER-α interacts with a
number of proteins, including c-Src, the p85 subunit of
phosphoinositide 3-kinase (PI3K), caveolin 1, and modulator
of non-genomic activity of ER (MNAR) [10,12], epidermal
growth factor receptor (EGFR), insulin-like growth factor
receptor 1 (IGFR1), and HER2 [13], and it rapidly increases
PIP2-phospholipase C activity and activates the mitogen-
activated protein kinase (MAPK) and PI3K/Akt pathways
[9,12,13]. More importantly, E2 is a potent inhibitor of
apoptosis and it regulates the expression of several apoptotic
proteins, including Bcl-2 in MCF-7, T47-D, and ZR-75-1
breast cancer cells [14].
Remarkably, there is another dimension to estrogen action
which contrasts with its ability to stimulate growth and inhibit
apoptosis. Physiologic E2 is also capable of inducing apop-
tosis in breast cancer cells that have been long-term
estrogen-deprived (LTED) or have been treated exhaustively
with anti-estrogens [15-23], prostate cancer cells [24],
neuronal cells [25], bone-derived cells [26], thymocytes [27],
and ER-transfected cells [28,29]. These data are particularly
interesting because high-dose estrogen therapy was used as
a treatment for post-menopausal patients with metastatic
breast cancer from the 1940s until the introduction of the
safer anti-estrogen tamoxifen in the 1970s [30]. At that time,
however, the mechanism of estrogen-induced tumor regres-
sion was not known. In this review, we will discuss the current
understanding of estrogen-induced apoptosis in breast
cancer and will summarize the possible mechanisms involved
in this estrogen-mediated process.
Estrogen-induced apoptosis: laboratory observations
Recent in vitro studies from our laboratory [18,31] and other
investigators [19,20,32] have shown that long-term estrogen
deprivation of hormone-dependent MCF-7 breast cancer
cells causes them to undergo adaptive changes in which
estradiol switches from being a proliferative agent to
paradoxically inhibiting growth and inducing apoptosis.
Interestingly, LTED cells also exhibit enhanced sensitivity to
estradiol in that an estradiol concentration that is three logs
lower can stimulate proliferation of these cells compared with
wild-type MCF-7 cells [19]. The development of hyper-
sensitivity to estradiol as a result of LTED is associated with
the upregulation of ER-α and the MAPK, PI3K, and mTOR
(mammalian target of rapamycin) growth factor pathways
[33]. In contrast, the apoptotic mechanisms of estradiol in
LTED cells are thought to involve the death receptors as well
as the mitochondrial pathways. Specific molecular events
include the activation of the Fas death receptor/Fas ligand
(FasL) complex [20], the release of cytochrome c from the
mitochondria and alterations in Bcl-2 [18,32], and the
downregulation of the anti-apoptotic factor nuclear factor-κ
[31,34]. It is important to note that estradiol also induces
apoptosis in in vivo models of anti-hormone drug resistance
[23,35,36]; however, the mechanisms by which this occurs
are not completely known.
Estrogen therapy and breast cancer: clinical
observations
Clinical data support the use of high-dose estrogen to treat
hormonally sensitive breast tumors [37-41]. In 1944, Sir
Alexander Haddow and colleagues [37] published the results
of their clinical trial with the synthetic estrogens triphenyl-
chlorethylene, triphenylmethylethylene, and stilbestrol adminis-
tered at high doses. They found that 10 out of 22 post-
menopausal patients with advanced mammary carcinomas,
who were treated with triphenylchlorethylene, had significant
regression of tumor growth. Five patients out of 14 who were
treated with high-dose stilbestrol produced similar responses.
Interestingly, the duration of the post-menopausal period was
found to be a critical factor affecting the success of this
therapy. For example, when the synthetic estrogen diethyl-
stilbestrol (DES) was administered at 15 mg per day, women
who had experienced the onset of menopause less than
1 year prior to therapy did not respond to DES; women who
had experienced the onset of menopause within 5 years of
menopause experienced a 7.9% objective response rate; and
women who reached menopause more than 10 years earlier
experienced a 22% response rate [41]. Despite the benefits,
however, there were significant systemic side effects asso-
ciated with high-dose estrogen therapy [37].
Cole and colleagues [39] reported the first clinical trial of the
anti-estrogen tamoxifen in women with late or recurrent
breast cancer and compared their findings with historical
data from women receiving DES. They concluded that the
levels of response were similar for DES and tamoxifen;
however, tamoxifen had a lower incidence of side effects.
Ingle and colleagues [30] compared tamoxifen with DES
directly and noted that response rates were similar but
tamoxifen had fewer side effects. Based on these data, the
use of high-dose estrogen for treatment of advanced breast
cancer fell out of favor, and tamoxifen became the standard
first-line endocrine therapy. The Ingle study [30] that
compared DES-treated and tamoxifen-treated patients was
followed up but surprisingly showed a survival advantage for
DES-treated patients [41]. Another small trial was conducted
by Lonning and colleagues [40] in post-menopausal patients
with advanced breast cancer exposed to multiple endocrine
therapies and revealed a 31% objective response rate with
DES therapy. More recently, Ellis and colleagues [42]reported that a daily dose of 6 mg of E2 could stop the
growth of tumors or even cause them to shrink in about 25%
of women with metastatic breast cancer that had developed
resistance to standard anti-hormonal therapy. These clinical
observations that estrogen can induce tumor regression after
several years of anti-hormonal therapy provide a clue that the
adaptation of cancer cells to low levels of estrogen might
sensitize cells to the apoptotic effect of estrogen. While the
mechanisms by which estrogen exerts its pro-apoptotic/anti-
tumor effect are not known, a growing body of evidence
suggests the involvement of the extrinsic (death receptor)
and intrinsic (mitochondrial) pathways in this process.
Two main pathways involved in apoptosis regulation
Apoptosis is a form of programmed cell death that plays a
critical role in the maintenance of tissue homeostasis [43]. It
is a highly regulated physiologic mechanism that removes
excess or damaged cells [43]. The dysregulation of apoptosis
is a hallmark of cancer, with both the loss of pro-apoptotic
signals and the gain of anti-apoptotic mechanisms contri-
buting to tumorigenesis [44]. The induction of apoptosis in
many cell types is achieved through the activation of the
extrinsic and the intrinsic pathways [45]. The extrinsic
pathway (Figure 1) is initiated by the interaction between
specific ligands and surface receptors, such as
CD95/Fas/Apo1, tumor necrosis factor (TNF) receptor 1
(TNFR1), TNF receptor 2 (TNFR2), and death receptors 3-6
(DR3-6) [46], which are able to deliver a death signal from
the extracellular microenvironment to the cytoplasm. Binding
of the ligand to the receptor induces receptor multimerization,
binding of Fas-associated death domain (FADD) adapter
protein, formation of the death-induced signaling complex
(DISC) which recruits the initiator caspases 8 and 10, and
subsequently activation of the effector caspases 3 and 7
[46]. In the intrinsic pathway (Figure 1), the integrity of the
mitochondrial membrane is controlled primarily by a balance
between the antagonistic actions of the proapoptotic and
antiapoptotic members of the Bcl-2 family [47] (please see
Table 1 for a detail description of common abbreviations
used in apoptosis). Bcl-2 family proteins comprise three
principal subfamilies: (a) anti-apoptotic members, including
Bcl-2/Bcl-xL, which possess the Bcl-2 homology (BH)
domains BH1, BH2, BH3, and BH4; (b) pro-apoptotic
members, such as Bax, Bak, and Bok, which have the BH1,
BH2, and BH3 domains; and (c) BH3-only proteins, such as
Bid, Bim, Bad, Bik, and Puma, which generally possess only
the BH3 domain [47]. The Bcl-2 family of proteins regulates
apoptosis by altering mitochondrial membrane permeabiliza-
tion and controlling the release of cytochrome c. Several lines
of evidence demonstrate that the Bcl-2 family functions are
controlled by growth factor signaling pathways, including the
PI3K/Akt, the JAK (Janus kinase)/Stat (signal transducer and
activator of transcription), and the Ras/MAPK pathways [48].
Phosphorylation and dephosphorylation of the members of
the Bcl-2 family of proteins by the above pathways regulate
the stabilization of mitochondrial homeostasis [48].
Signaling pathways implicated in estrogen-
induced apoptosis
The extrinsic (receptor-mediated) pathway
Mechanistic studies have used either LTED MCF-7 breast
cancer cells [18,20,31,34] or selective ER modulator
(SERM) (tamoxifen or raloxifene)-stimulated tumor models
[23,35,36,49-51] to demonstrate the involvement of the
Fas/FasL death signaling pathway in the paradoxical
apoptotic/anti-tumor effects of E2. Song and colleagues [20]
were the first to demonstrate that E2 caused apoptosis in
breast cancer cells that were adapted to grow in an E2-free
environment for prolonged periods. They reported that their
LTED cells, which were derived by growing wild-type MCF-7
breast cancer cells under long-term (6 to 24 months)
estrogen-deprived conditions, expressed high levels of Fas
compared with the parental MCF-7 cells and that treatment of
these cells with E2 resulted in a marked increase in FasL.
This finding was confirmed by Osipo and colleagues [35],
who reported that physiologic levels of E2 induced regres-
sion of tamoxifen-resistant breast cancer tumors by inducing
Fas expression and suppressing the anti-apoptotic/pro-
survival factors nuclear factor-kappa-B (NF-κB) and HER2/
neu. A similar finding was reported by Liu and colleagues
[49] in raloxifene-resistant MCF-7 cells in vitro and in vivo. In
addition, Tonetti and colleagues [50,51] previously reported
that stable overexpression of protein kinase C-alpha (PKC-α)
in hormone-responsive T47D:A18 breast cancer cells
(T47D:A18/PKC-α) produced a hormone-independent/
tamoxifen-resistant and E2-inhibitory phenotype in vivo
[50,51]. Using the T47D:A18/PKC-α-overexpressing tumor
model, they further demonstrated that E2-induced regression
and apoptosis were due to increased expression of Fas/FasL
proteins and downregulation of the pro-survival Akt pathway
[36]. In all of these model systems, the ER-α was shown to
be critical for E2-induced tumor regression and apoptosis.
Blockade of the ER-α signaling pathway using the pure anti-
estrogen fulvestrant completely inhibited the apoptotic effect
of E2 [20,35,36,49].
It is worth noting that a putative estrogen-responsive element
(ERE) has been identified in the promoter region of the FasL
gene [52], suggesting direct estrogen effects on FasL
expression. In addition, a number of transactivating factors
have been identified as regulators of FasL gene expression,
including activator protein 1 (AP-1) [53] and specificity
protein 1 (Sp-1) [54]. Sp-1 is involved in the transcriptional
regulation of many genes and has also been identified to be
important in the regulation of FasL gene expression and
apoptosis. Indeed, this transcription factor is able to activate
FasL promoter via a distinct recognition element, and
inducible FasL promoter activation is abrogated by the
expression of the dominant-negative mutant form of Sp-1
[54]. Functional studies have demonstrated that Sp-1 is a
crucial effector of E2 signal in enhancing FasL gene
expression. For instance, it is well known that ERs can
transactivate gene promoters without directly binding to DNA
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in promoter regions lacking TATA box. This has been
investigated extensively in relation to protein complexes
involving Sp-1 and ER-α at GC boxes, which are classic
binding sites for members of the Sp-1 family of transcription
factors. Sp-1 protein plays an important role in the regulation
of mammalian and viral genes, and recent results have shown
that E2 responsiveness of c-fos, cathepsin D, retinoic acid,
and insulin-like grow factor-binding protein 4 gene expression
in breast cancer cells is linked to specific GC-rich promoter
sequences that bind ER/Sp-1 complex in which only Sp-1
protein binds DNA [55-59]. Thus, it is possible that, when E2
upregulates FasL production in these different model
systems, an apoptotic signal is initiated by FasL binding on
Fas receptor.
The intrinsic (mitochondrial) pathway
Over the last several years, there has been accumulating
evidence that, apart from the extrinsic/receptor-mediated
pathway, the mitochondrial (intrinsic) pathway plays a role in
E2-induced apoptosis. Indeed, we [18] have previously
reported that, in our LTED breast cancer cell line, MCF-7:5C,
E2 treatment markedly increased the expression of several
pro-apoptotic proteins, including, Bax, Bak, Bim, Noxa, Puma,
and p53, and that blockade of Bax and Bim expression using
short interfering RNAs (siRNAs) almost completely reversed
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Figure 1
The two main pathways involved in apoptosis regulation. (a) The extrinsic pathway begins outside the cell through the activation of receptors on
the cell surface by specific molecules known as pro-apoptotic ligands, including CD95L/FasL (receptor CD95/Fas). Once activated, the death
domains of these receptors bind to the adapter protein Fas-associated death domain (FADD), resulting in the assembly of death-induced signaling
complex (DISC) and recruitment and assembly of initiator caspases 8 and 10. The two caspases are stimulated and processed, releasing active
enzyme molecules into the cytosol, where they activate caspases 3, 6, and 7, thereby converging on the intrinsic pathway. (b) The intrinsic
(mitochondrial) pathway is initiated in response to cellular signals resulting from DNA damage, a defective cell cycle, detachment from the
extracellular matrix, hypoxia, loss of cell survival factors, or other types of severe cell stress. This triggers activation of specific members of the pro-
apoptotic Bcl-2 protein family involved in the promotion of apoptosis, Puma and Noxa, which in turn activate the pro-apoptotic proteins Bax or Bak.
These two proteins move to the mitochondrial membrane and disrupt the anti-apoptotic function of the Bcl-2 family proteins, allowing for
permeabilization of the mitochondrial membrane. Apaf-1, apoptotic protease activating factor 1; Bad, Bcl-2/Bcl-XL-associated death domain
protein; Bak, Bcl-2 homologous antagonist-killer protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Bcl-XL, Bcl-2-related gene,
long form; Bid, Bcl-2-interacting domain; Bim, Bcl-2-interacting mediator of cell death; Casp, caspase; Cyt c, cytochrome c; E2, 17β-estradiol; ER,
estrogen receptor; ERE, estrogen-responsive element; FasL, Fas ligand; FLIP, FLICE-inhibitory protein; IAP, inhibitor of apoptosis; Noxa, phorbol-
12-myristate-13-acetate-induced protein 1; Puma, p53-upregulated modulator of apoptosis.the apoptotic effect of E2 in these cells. E2 treatment also led
to a loss of mitochondrial potential and a dramatic increase in
the release of cytochrome c from the mitochondria, which
resulted in activation of caspases 7 and 9 and cleavage of
poly(ADP-ribose)polymerase (PARP). Furthermore, over-
expression of anti-apoptotic Bcl-xL completely blocked E2-
induced apoptosis in MCF-7:5C cells. Interestingly,
microarray analysis of wild-type MCF-7 cells and LTED MCF-
7:5C cells revealed significant differences in the gene
expression profile between the two cell lines following E2
treatment (Figure 2a). In particular, E2 treatment caused a
marked increase in several pro-apoptotic genes in MCF-7:5C
cells compared with wild-type MCF-7 cells (Figure 2b).
In two other estrogen-deprived breast cancer lines, LTED and
E8CASS, basal Bcl-2 level was greatly elevated and knock-
down of Bcl-2 expression with siRNA markedly sensitized
these cells to the apoptotic action of E2 [32]. A similar
finding was reported for another LTED breast cancer cell line,
MCF-7:2A, which expressed elevated basal levels of Bcl-2
and was initially resistant to E2-induced apoptosis [34]. We
found that suppression of Bcl-2 expression in these cells
enhanced the apoptotic effect of E2 by almost fivefold [34],
thus suggesting an important role for this protein in the
apoptotic action of E2. Currently, there is renewed interest in
developing small-molecule inhibitors of Bcl-2 [60] as anti-
cancer cell and anti-angiogenic agents. The Bcl-2 antisense
oligonucleotide, Oblimersen (Genasense; Genta Incorpora-
ted, Berkeley Heights, NJ, USA), which works by blocking Bcl-
2 protein production, is now in a phase III clinical trial [61].
Inhibition of the survival pathways Akt and nuclear
factor-kappa-B
The existence of various checkpoints in apoptosis reveals a
complex balance between cell survival and cell death in cells.
Two of the main signaling pathways involved in cell survival
are the Akt and NF-κB signaling pathways (Figure 3). The
PI3K/Akt/protein kinase B (PKB) pathway plays a central role
in a variety of cellular processes, including cell growth,
proliferation, motility, and survival in both normal and tumor
cells. It impinges upon a remarkable array of intracellular
events that influence either directly or indirectly whether a cell
will undergo apoptosis. Many of the transforming events in
breast cancer are a result of enhanced signaling of the
PI3K/Akt pathway. Akt, also called PKB, is the human
homologue of the viral oncogene v-akt [62], which regulates
multiple targets, including several apoptotic genes. In a series
of publications [63,64], Akt was found to mediate phos-
phorylation and hence inactivation of pro-apoptotic factors
like Bad, which controls the release of cytochrome c,
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Table 1
Description of common abbreviations used in apoptosis and signal transduction
Abbreviation Meaning Synonyms
Bad Bcl-2/Bcl-XL-associated death domain protein BH3-only member of the Bcl-2 family
Bak Bcl-2 homologous antagonist-killer protein Multi-BH domain pro-apoptosis protein
Bax Bcl-2-associated X protein Multi-BH domain pro-apoptosis protein
Bcl-2 B-cell lymphoma-2 Defining member of the family; originally characterized as an 
oncogene
Bcl-XL Bcl-2-related gene, long form Bcl-XS is a shorter splice variant that is pro-apoptotic
Bim Bcl-2-interacting mediator of cell death BH3-only member of the Bcl-2 family
IκBI nhibitor of NF-κB Interacts with NF-κB
IKK IκB kinase Phosphorylates IκB to promote its degradation
MDM2 Murine double minute Negative regulator of the p53 tumor suppressor
NF-κBN uclear factor-kappa type B Originally linked with enhancement of immunoglobulin kappa 
light-chain gene
p53 53 kDa protein Tumor-suppressor protein
PDK-1 3-phosphoinositide-dependent protein kinase 1 Master kinase that is crucial for the activation of Akt/PKB
PI3K Phosphoinositide 3-kinase Phosphatidylinositol 3-kinase; PI 3-kinase; PtdIns3K
PKB Protein kinase B Akt; RACK (related to A and C kinase); has PH domain
PMAIP-1/Noxa Phorbol-12-myristate-13-acetate-induced protein 1 BH3-only member of the Bcl-2 family and candidate mediator 
of p53-induced apoptosis
PUMA p53-upregulated modulator of apoptosis BH3-only member of the Bcl-2 family
BH, Bcl-2 (B-cell lymphoma-2) homology.procaspase 9, and Forkhead transcription factors. Akt also
activates anti-apoptotic genes, including cyclic-AMP response
element-binding protein (CREB) and IκB (inhibitor of NF-κB)
kinase (IKK), the primary regulator of NF-κB activity.
Several groups have demonstrated that E2 can also inhibit
the P13K/Akt signaling pathway and consequently induce
apoptosis of cancer cells. In tamoxifen-resistant PKC-α-
overexpressing cells, E2-induced tumor regression is
associated with the downregulation of phosphorylated Akt
[36]. In addition, in LTED MCF-7:5C and MCF-7:2A breast
cancer cells, the basal level of phosphorylated Akt is
markedly upregulated and E2 treatment significantly reduces
its expression (Figure 4). There is also evidence that, in MCF-
7.beclin-overexpressing cells, E2 treatment significantly
reduces Akt phosphorylation, which is associated with a
decrease in cell proliferation [65]. Akt, therefore, is con-
sidered a rational target for cancer therapies and inhibitors of
the PI3K/Akt pathway have been identified [66].
NF-κB is one of the most studied transcription factors in
mammalian cells. Its family is composed of five members:
RELA (p65), RELB, REL (cRel), NF-κB1 (p50 and its
precursor p105), and NF-κB2 (p52 and its precursor p100)
[67]. These proteins form homodimeric and heterodimeric
complexes, and the activity of these proteins is regulated by
two major pathways: the classical or canonical NF-κB activa-
tion pathway [67] and the non-canonical NF-κB activation
pathway [67]. One of the most documented functions of
NF-κB is its ability to promote cell survival through the
induction of target genes (Figure 3), the products of which
inhibit the apoptotic machinery in normal and malignant cells
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Figure 2
Gene expression profile of wild-type MCF-7 cells and long-term estrogen-deprived (LTED) MCF-7:5C breast cancer cells following 17β-estradiol
(E2) treatment. Cells were treated with 1 nM E2 for 48 hours, and RNA was hybridized to the Affymetrix Human Genome U133 Plus 2.0 Arrays
(Affymetrix, Santa Clara, CA, USA). (a) Hierarchical clustering dendogram of E2-regulated genes in MCF-7 and MCF-7:5C cells. Microarray
expression data for each cell line were first filtered for minimal intra-replicate standard deviation (<0.25) and a standard deviation between all
samples of at least 0.25. This generated a total of 2,743 genes. In addition, genes displaying a minimum of twofold upregulation or downregulation
by E2 in either MCF-7 or MCF-7:5C cells were extracted, revealing a set of 539 differentially expressed, E2-regulated genes. (b) E2 regulation of
pro-apoptotic and anti-apoptotic genes in MCF-7 cells (top panel) and MCF-7:5C cells (bottom panel). Bak, Bcl-2 homologous antagonist-killer
protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Bim, Bcl-2-interacting mediator of cell death; GADD45β, growth arrest and
DNA damage; p53, 53 kDa protein.[68]. Indeed, overall reduction in NF-κB activity is associated
with an increased apoptotic index in many cell types [68].
Furthermore, NF-κB activation has been shown to inhibit p53-
dependent apoptosis following expression of the oncogene
AP12/MALT1 [69]. Thus, blocking this signaling pathway
might be a promising option to improve the efficacy of
conventional anti-cancer therapies.
Several studies have shown that E2 can inhibit the activity of
NF-κB and thereby increase apoptosis. For example, Osipo
and colleagues [35] reported that, in tamoxifen-resistant
MCF-7 tumors, E2 treatment almost completely down-
regulated the level of the NF-κB p65 subunit protein, which
correlated with the anti-proliferative and pro-apoptotic effects
of E2 in this model system. These investigators also reported
that cyclooxygenase 2 (COX-2), an NF-κB-responsive gene,
was markedly reduced in E2-treated tamoxifen-stimulated
MCF-7 tumors [35]. They concluded from this finding that
E2-induced apoptosis and tumor regression in tamoxifen-
resistant MCF-7 tumors occurred, in part, through suppres-
sion of the pro-survival/anti-apoptotic factor NF-κB. It should
be noted that NF-κB expression is also markedly elevated in
raloxifene-resistant MCF-7 breast cancer cells [49] and LTED
breast cancer cells (Figure 4) and its downregulation by E2 is
associated with the suppression of proliferation and the
induction of apoptosis [31,32,70].
Glutathione suppression and estrogen-induced
apoptosis
Previous studies have reported that, apart from its action on
the mitochondria, Bcl-2 functions as an anti-oxidant to block
apoptosis and that Bcl-2 protein levels and glutathione
(GSH) intracellular concentration are coordinately regulated,
with a decrease in either favoring cell death [71]. It is
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Figure 3
Summary of some of the key processes regulated in the cytoplasm, at the mitochondria, in the nucleus, or in the cytosol by the PI3K/Akt pathway in
controlling apoptosis. The positive events controlled either directly or indirectly by PI3K/Akt are indicated by arrows, whereas blocked lines
represent events that have inhibitory effects. Bad, Bcl-2/Bcl-XL-associated death domain protein; Bax, Bcl-2-associated X protein; Bcl-XL, Bcl-2-
related gene, long form; Bim, Bcl-2-interacting mediator of cell death; FasL, Fas ligand; IAP, inhibitor of apoptosis; IκB, inhibitor of nuclear factor-
kappa-B; IKK, IκB (inhibitor of nuclear factor-kappa-B) kinase; Mcl-1, myeloid cell leukemia 1; Mdm2, murine double minute; NF-κB, nuclear factor-
kappa-B; p53, 53 kDa protein; PDK-1, phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide 3-kinase; PKB/Akt, protein kinase B.believed that one mechanism by which Bcl-2 may function as
an anti-oxidant is through upregulation of GSH, leading to
rapid detoxification of reactive oxygen species and inhibition
of free radical-mediated mitochondrial damage. Bcl-2 also
has the ability to shift the entire cellular redox potential to a
more reduced state which is independent of its effect on
GSH levels [72].
GSH is a water-soluble tripeptide composed of glutamine,
cysteine, and glycine. It is the most abundant intracellular
small-molecule thiol present in mammalian cells, and it serves
as a potent intracellular anti-oxidant, protecting cells from
toxins such as free radicals [73]. Changes in GSH homeo-
stasis have been implicated in the etiology and progression of
a variety of human diseases, including breast cancer [74],
and studies have shown that elevated levels of GSH prevent
apoptotic cell death whereas depletion of GSH facilitates
apoptosis [75]. L-buthionine sulfoximine (BSO) is a specific γ-
glutamylcysteine synthetase inhibitor that blocks the rate-
limiting step of GSH biosynthesis and, in doing so, depletes
the intracellular GSH pool in both cultured cells and whole
animals [73].
Recently, we reported that GSH participates in retarding
apoptosis in anti-hormone-resistant LTED MCF-7:2A human
breast cancer cells and that depletion of this molecule by
BSO, a potent inhibitor of GSH biosynthesis, sensitized
these resistant cells to E2-induced apoptosis [34]. GSH
levels were elevated approximately 60% in MCF-7:2A cells
compared with wild-type MCF-7 cells and these cells failed to
undergo apoptosis following 1 week of E2 treatment. In the
presence of BSO (100 μM), however, 1 nM E2 caused a
dramatic increase in apoptosis which was observed as early
as 48 hours, with maximum induction observed at day 7. The
apoptotic effect of E2 plus BSO in MCF-7:2A cells was
associated with a marked decreased in Bcl-2 and phosphory-
lated Bcl-2 protein levels, mitochondrial membrane disruption
and cytochrome c release, caspase 7 activation, and PARP
cleavage [34]. It is important to note that the concentration of
BSO (100 μM) used in this study is clinically achievable
without significant side effects [76]. Furthermore, early-phase
clinical trials of BSO at doses resulting in both peripheral and
tumor GSH depletion show that BSO can be safely
administered with melphalan (L-PAM) to patients with
refractory disease [77,78]. Thus, it is possible that future
clinical studies of BSO infusions combined with low-dose
estrogen hold the promise of improving disease control for
patients with anti-hormone-resistant ER-positive metastatic
breast cancer.
c-Jun N-terminal kinase signaling pathway
There is also evidence that E2 induces apoptosis by
regulating the c-Jun N-terminal kinase (JNK) pathway. JNKs
are a group of MAPKs that bind the NH2-terminal activation
domain of the transcription factor c-jun and phosphorylate c-
jun on amino acid residues Ser-63 and Ser-73 [79]. JNKs are
stimulated by multiple factors, including cytokines, DNA-
damaging agents, and environmental stresses, and are
important in controlling programmed cell death or apoptosis.
The inhibition of JNKs has been shown to enhance
chemotherapy-induced inhibition of tumor cell growth,
suggesting that JNKs may provide a molecular target for the
treatment of cancer [79]. Recently, Altiok and colleagues [80]
reported that, under low growth-stimulated conditions, high
concentrations (1 μM) of E2 induced apoptosis and conco-
mitantly increased phosphorylation of c-jun in ER-positive
MCF-7 breast cancer cells but not in ER-negative MDA-MB
231 cells, thus suggesting an ER-mediated event. Interest-
ingly, when the JNK signaling pathway was disrupted by the
JNK inhibitor SP600125, the ability of E2 to inhibit the
growth of MCF-7 cells and to induce apoptosis was com-
pletely blocked. More recently, we reported that JNK
activation (as measured by the increased levels of phospho-
JNK1/2 and the JNK substrate phospho-c-Jun) was increased
by low-dose E2 in the presence of BSO in anti-hormone-
resistant MCF-7:2A cells [34]. While the exact mechanism by
which JNK promotes apoptosis is not currently known, the
phosphorylation of transcription factors such as c-jun and
p53, as well as pro- and anti-apoptotic Bcl-2 family members,
has been suggested to be of importance [81]. The treatment
with BSO plus E2 markedly increased phosphorylated c-jun
in MCF-7:2A cells and decreased phosphorylated Bcl-2 in
these cells. These findings thus suggest that BSO plus E2
might mediate their apoptotic effect, in part, through
activation of JNK.
Clinical exploitation of estrogen-induced
apoptosis
Laboratory studies uniformly demonstrate that low concen-
trations of estrogen can cause apoptotic tumor cell death
following profound estrogen deprivation with anti-hormones.
The question that now needs to be answered is how can this
new laboratory knowledge be translated into patient care?
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Figure 4
E2 (17β-estradiol) regulation of survival pathways in wild-type MCF-7
cells and long-term estrogen-deprived MCF-7:5C and MCF-7:2A
breast cancer cells. Cells were treated with 1 nM E2 for 72 hours, and
protein lysates were analyzed by Western blot for p-Akt, Akt, and
nuclear factor-kappa-B (NF-κB). β-actin was used as a loading control.Recently, Ellis and colleagues [42] reported that low-dose E2
(6 mg daily: 2 mg three times a day) produced a 25%
response rate for patients with ER-positive AI-resistant
advanced breast cancer. This number is slightly lower than
the 31% objective response rate reported by Lonning and
colleagues [40] with DES (5 mg three times a day) in post-
menopausal women heavily pre-treated with endocrine
therapy. The Lonning study [40] recruited patients with
advanced breast cancer who were previously treated with
exhaustive endocrine therapy. Of the 32 patients enrolled,
four patients obtained complete response (CR) and six
patients obtained partial response. In contrast, the Ellis study
[42] recruited patients who were treated with an AI with 24
or more weeks of progression-free survival or who had a
relapse after 2 or more years of adjuvant AI. Interestingly,
there were no CRs in the Ellis study [42]. Clinical obser-
vations suggest that the duration of the post-menopausal
period is one of the crucial factors affecting the success of
low-dose estrogen therapy. In other words, the longer the
estrogen deprivation period, the higher the likelihood of a
response to low-dose estrogen. The fact that there were four
CRs in the Lonning study [40] but none in the Ellis study [42]
suggests the need for extensive estrogen blockade or
withdrawal to get the best effects from low-dose estrogen.
Estrogen and bone remodeling
In addition to its role in female sexual development and
reproductive physiology, estrogen plays a key role in bone
cell metabolism. Estrogen contributes to the strength of a
woman’s skeleton by maintaining bone density. Bone is a
dynamic tissue that is constantly being reshaped by
osteoblasts, which build bone, and osteoclasts, which resorb
bone [82]. This dynamic process is called remodeling. Osteo-
blasts are derived from pleiotropic mesenchymal stem cells in
the bone marrow, whereas osteoclasts are multinuclear
macrophage-like cells derived from hematopoietic stem cells
also in the bone marrow. Bone resorption and deposition are
tightly coupled, and their balance defines both bone mass as
well as quality. The regulation of bone remodeling is complex;
however, estrogen is thought to play a key role in this process
[82]. Estrogen inhibits bone remodeling and bone resorption
and enhances bone formation. Conversely, loss of estrogen,
due to menopause or surgical oophorectomy, leads to an
increased rate of remodeling and tilts the balance between
bone resorption and formation in favor of the former [83].
Estrogen deficiency in post-menopausal women frequently
leads to osteoporosis, the most common skeletal disorder.
The imbalance in bone turnover that is induced by estrogen
deficiency in women and female rodents can be ameliorated
with estrogen/progestin hormone therapy or SERMs [84].
The main effect of estrogen on bone remodeling is to
decrease activation frequency and subsequently decrease
the numbers of osteoclasts and osteoblasts. Its effects on
osteoclasts are mainly indirect and mediated by products
secreted by the osteoblast. These products include RANK-L
(the ligand of the receptor activator of NF-κB), colony-stimu-
lating factor 1 (CSF-1), and osteoprotegerin (OPG). They
regulate the differentiation of osteoclast precursors to osteo-
clasts and then modulate the activity of the mature
osteoclasts and regulate its rate of apoptosis. Estrogen also
decreases the secretion of the pro-inflammatory cytokines
interleukin (IL) 1, IL-6, and TNF-α by marrow monocytes,
resulting in decreased production of OPG and RANK-L by
the osteoblasts, thereby decreasing the rate of production of
osteoclasts, their activity, and their survival [82]. There is also
evidence that estrogen has direct effects on osteoclast
lineage cells. It induces apoptosis of these cells and it
suppresses RANK-L-induced osteoclast differentiation by
blocking RANK-L/macrophage colony-stimulating factor
(M-CSF)-induced AP-1-dependent transcription through a
reduction of c-jun activity [85]. Moreover, estrogen has been
shown to inhibit the activity of mature osteoclasts through
direct, receptor-mediated mechanisms. Indeed, a recent
study by Nakamura and colleagues [86] reported that
estrogen, acting via the ER-α, induced apoptosis in osteo-
clasts through activation of the Fas/FasL system and that this
leads to suppression of bone resorption through truncating
the short life span of differentiated osteoclasts.
Future perspective
Estrogen is a potent mitogen that stimulates cell proliferation
and prevents cell death in breast cancer cells through
activation of the ER. Paradoxically, estrogen is also capable
of inducing tumor regression of hormone-dependent breast
cancer in post-menopausal women who have been treated
exhaustively with anti-hormones. Pre-clinical studies suggest
that the evolution of anti-hormone resistance over years of
therapy reconfigures the survival mechanism of the breast
cancer cell so that estrogen no longer functions as a survival
factor but as a death signal. It is this reconfiguration that
helps to explain the ‘two faces’ of estrogen: the ability to
stimulate growth and to induce death. Interestingly, estrogen
also induces tumor regression in raloxifene-resistant
endometrial tumors (G Balaburski and VC Jordan, personal
communication) and it prevents bone loss by inducing
apoptosis in osteoclasts, suggesting a universal principle.
Pre-clinical data [34] clearly show that it is possible to
enhance the apoptotic effect of low-dose E2 by combining it
with BSO. Hence, the combination of BSO and E2 could be
used to improve the efficacy of E2 as an apoptotic agent if
GSH depletion is fundamental to tumor cell survival. Phase I
clinical trials of BSO at doses resulting in both peripheral and
tumor GSH depletion show that BSO can be safely adminis-
tered to patients with refractory disease. BSO was adminis-
tered intravenously twice daily either alone or together with
chemotherapy to cancer patients whose disease had pro-
gressed despite multiple lines of previous chemotherapy [78].
Inhibitors of survival pathways also have the ability to enhance
the apoptotic/growth-inhibitory effects of E2. Several groups
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tumor agents [87]. These inhibitors encompass various drugs
that bind the anti-apoptotic Bcl-2 family members with more
or less efficacy. Oblimersen (Genasense; G3139) is an anti-
Bcl-2 antisense oligonucleotide that has reached phase III
clinical trials in combination therapy [88]. There are also
natural inhibitors of Bcl-2, which include tea polyphenols
such as catechins and theaflavins [89].
Conclusions
The discovery of a new biology of E2-induced apoptosis
provides a unique signal transduction pathway to exploit in
the treatment of metastatic breast cancer that has become
refractory to exhaustive anti-hormone therapy. The clinical
clues with the use of high-dose estrogen therapy have now
been supported by a wealth of laboratory data defining
apoptotic mechanisms. It is plausible to consider that the
methodical evaluation of monoclonal antibodies and small-
molecule tyrosine kinase inhibitors to prevent breast cancer
survival could amplify the apoptotic actions of estradiol in a
select group of patients. Indeed, if a study of the molecular
biology of estrogen-induced apoptosis can define the
mechanism precisely, then the molecules involved will
become the target for a new drug group. These new drugs
may be able to precipitate apoptosis in ER-negative breast
tumors or indeed be used universally to treat cancer types
other than breast cancer.
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